ArticleRadiology. Imaging cancer2026
Preoperative CT-based Radiomics for Predicting Response to Neoadjuvant Chemoimmunotherapy in Esophageal Squamous Cell Carcinoma.
Article in Radiology. Imaging cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To evaluate the performance of a CT-based model combining two-dimensional (2D) and two-and-a-half-dimensional (2.5D) deep learning (DL) with radiomic features in predicting neoadjuvant chemoimmunotherapy response in patients with esophageal squamous cell carcinoma (ESCC). Materials and Methods In this retrospective study, patients with ESCC from Sun Yat-sen Cancer Center between May 2020 and January 2023 were divided into training (80%) and internal validation (20%) groups, while an external testing group was obtained from Nanfang Hospital between January 2021 and March 2023. Radiomic features were extracted manually, while 2D and 2.5D deep transfer learning (DTL) features were derived from pretrained DL networks. The optimal model was selected based on a comparison of the areas under the receiver operating characteristic curves (AUCs). Results In total, 251 patients (mean age, 59.91 years ± 7.63; 209 male and 42 female) were included in the study, with 157 and 94 patients from centers 1 and 2, respectively. The support vector machine (SVM) model outperformed the other radiomic and DL models, while ResNet18 had the best predictive performance among the 2D and 2.5D DL models. The SVM model with ResNet18-based DTL features showed the best performance, achieving AUC values of 0.85 (95% CI: 0.76, 0.91) for 2D DTL and 0.84 (95% CI: 0.75, 0.91) for 2.5D DTL in the external testing group. Conclusion A fusion model integrating 2D and 2.5D DTL and radiomic features effectively predicted the neoadjuvant chemoimmunotherapy response in patients with ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.